Skip to main content

Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung Cancer

Objective

Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds.
The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in
economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery
due to co-morbidities.

Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive
intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to
deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be
delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.

The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading
companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking
funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval.
This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative
market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes
increase.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/health sciences/public and environmental health
  • /medical and health sciences/clinical medicine/surgery
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

H2020-EIC-FTI-2018-2020
See other projects for this call

Funding Scheme

IA - Innovation action

Coordinator

ENDOWAVE LIMITED
Address
88 Harcourt Street
D02D K18 Dublin
Ireland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 1 656 953

Participants (4)

HUBER + SUHNER AG
Switzerland
EU contribution
€ 358 043
Address
Degersheimerstrasse 14
9100 Herisau
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
NATIONAL UNIVERSITY OF IRELAND GALWAY
Ireland
EU contribution
€ 79 563
Address
University Road
H91 Galway
Activity type
Higher or Secondary Education Establishments
LEANFA SRL
Italy
EU contribution
€ 329 277
Address
Vico Carlo Alberto Dalla Chiesa 6
70037 Ruvo Di Puglia Ba
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TELEFLEX MEDICAL EUROPE LIMITED
Ireland
EU contribution
€ 570 777
Address
Ida Business And Technology Park, Dublin Road
Athlone Co. Westmeath
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)